Champions Oncology (CSBR) Research & Development (2010 - 2026)
Champions Oncology (CSBR) posted quarterly Research & Development of $2.3 million for Q2 2026, up 1.73% year-over-year from $2.3 million in Q2 2025, and down 11.89% quarter-over-quarter from $2.7 million in Q1 2026.
Champions Oncology (CSBR) Research & Development (2010 - 2026) Analysis & Trends
Champions Oncology's Research & Development history runs 17 years deep, the most recent figure standing at $2.3 million for Q2 2026.
- In Q2 2026, Research & Development rose 1.73% year-over-year to $2.3 million; the TTM figure through Apr 2026 stood at $9.7 million (up 28.73% YoY), while the FY2026 annual figure was $9.3 million, up 23.5% from the prior year.
- Research & Development for Q2 2026 stood at $2.3 million, down from $2.7 million in the prior quarter.
- The five-year high for Research & Development was $3.2 million in Q1 2023, with the low at $1.7 million in Q3 2024.
- The 5-year median for Research & Development is $2.4 million (2023), against an average of $2.4 million.
- The sharpest annual moves came in 2024 and 2025: Research & Development slumped 39.89% in 2024, then surged 49.4% in 2025.
- Champions Oncology's Research & Development stood at $2.6 million in 2022, then declined by 3.42% to $2.5 million in 2023, then slumped by 30.38% to $1.8 million in 2024, then soared by 49.4% to $2.6 million in 2025, then retreated by 10.21% to $2.3 million in 2026.
- Business Quant data shows CSBR's Research & Development at $2.3 million in Q2 2026, $2.7 million in Q1 2026, and $2.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn | 2.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 2.35 Mn |
| Jan 31, 2026 | 2.67 Mn |
| Oct 31, 2025 | 2.62 Mn |
| Jul 31, 2025 | 2.08 Mn |
| Apr 30, 2025 | 2.31 Mn |
| Jan 31, 2025 | 1.81 Mn |
| Oct 31, 2024 | 1.75 Mn |
| Jul 31, 2024 | 1.68 Mn |
| Apr 30, 2024 | 2.05 Mn |
| Jan 31, 2024 | 2.19 Mn |
| Oct 31, 2023 | 2.52 Mn |
| Jul 31, 2023 | 2.79 Mn |
| Apr 30, 2023 | 2.85 Mn |
| Jan 31, 2023 | 3.20 Mn |
| Oct 31, 2022 | 2.60 Mn |
| Jul 31, 2022 | 2.89 Mn |
| Apr 30, 2022 | 2.59 Mn |
| Jan 31, 2022 | 2.18 Mn |
| Oct 31, 2021 | 2.30 Mn |
| Jul 31, 2021 | 2.30 Mn |